Although lenvatinib has shown antitumor effects in hepatocellular carcinoma, long-term safety data are lacking.
Yael Celermajer, MD
Although lenvatinib (Lenvima) has shown antitumor effects in hepatocellular carcinoma (HCC), long-term safety data are lacking. In general, lenvatinib is associated with favorable efficacy, but it is also associated with adverse effects (AEs) that require monitoring and proactive management by the clinician.
Findings from a real-world safety and tolerability trial demonstrated that the agent’s safety profile was similar to that observed in initial clinical trials, according to a poster presented at The Liver Meeting Digital Experience, the American Association for the Study of Liver Diseases annual conference. Yael Celermajer, MD, and coinvestigators noted in their poster that hypothyroidism occurred more frequently in this real-world cohort (39%). This AE was independently associated with improved overall survival (OS) in lenvatinib-treated patients with HCC.
Fifty-one patients were treated with lenvatinib between December 2018 and June 2020, with 90% of patients experiencing an AE. Hypertension and hypothyroidism were the most common AEs, with 47% of patients reporting new or worsening hypertension and 39% reporting hypothyroidism (FIGURE see page 47).
Among patients reporting new or worsening hypertension, 88% required antihypertensive medication; 15 patients required 1 antihypertensive agent, 5 patients required 2 agents, and 2 patients required more than 2 agents. Among patients who developed hypothyroidism (thyroid stimulating hormone > 4.20 mIU/L), 75% required thyroid replacement therapy.
Severe AEs included duodenal ulcer (2%), malignant hypertension (2%), anaphylaxis (2%), and sudden unexplained death after starting therapy (2%). Investigators reported that 41% of patients had a dose reduction and that treatment was temporarily held in 35% of patients.
Patients who developed hypothyroidism while on therapy had a greater median OS than those who did not. The median OS for patients with normal thyroid function was 309 days; for those with hypothyroidism, the median OS was not reached (P = .033).
On univariable analysis, predictors of survival were hypothyroidism, and baseline albumin and bilirubin levels. On multivariable analysis, albumin and bilirubin levels remained significant.
The primary objectives of the study were to elucidate the type, rate, and severity of AEs. Secondary objectives were to determine rates of dose reduction, discontinuation, and OS.
Patients were a mean age of 64 years, 44 patients were male, and 43 patients had received prior treatment for HCC, specifically transarterial chemoembolization (57%), resection (31%), ablation (20%), sorafenib ([Nexavar], 20%), and selective internal radiation therapy (10%).
At a median follow-up of 216 days, 59% of patients had ceased treatment with lenvatinib. Investigators reported that reasons for stopping therapy were disease progression (31%), intolerance (20%), and death while on therapy (8%).
Forty-seven percent of patients had preexisting hypertension, and 90% had cirrhosis caused by hepatitis C (43%), hepatitis B (20%), and alcohol (16%). Regarding prognosis, 74% of patients were Child-Pugh A, 24% were Child-Pugh B, and 2% were Child-Pugh C.
Further, 63% of patients were Barcelona Clinic Liver Cancer (BCLC) stage C and 37% were BCLC stage B.
Lenvatinib gained its approval for the first-line treatment of patients with unresectable HCC based on the open-label, noninferiority REFLECT trial (NCT01761266).2 The trial’s findings showed that lenvatinib was noninferior but not statistically superior to sorafenib (Nexavar) for OS (HR, 0.92; 95% CI, 0.79- 1.06). The most common AEs observed in the lenvatinib-treated patients with HCC in order of decreasing frequency were hypertension, fatigue, diarrhea, and decreased appetite.
References:
1. Celermajer Y, Prince DS, Stratton E, et al. Real-world safety and tolerability data for lenvatinib use in unresectable hepatocellular cancer. Presented at: American Association for the Study of Liver Diseases The Liver Meeting Digital Experience; November 13-16, 2020; virtual. Abstract 1167. Accessed January 12, 2021. https://bit.ly/2LQJaFC
2. FDA approves lenvatinib for unresectable hepatocellular carcinoma. FDA. Updated August 16, 2018. Accessed January 13, 2021. https://bit.ly/3i8l5Vw
Leon-Ferre Explores Targeting of PIK3CA Alterations in ER+ Breast Cancer
July 24th 2024During a live Community Case Forum event in partnership with the Minnesota Society of Clinical Oncology, Roberto A. Leon-Ferre, MD, discussed drugs targeting PIK3CA alterations in patients with ER+ metastatic breast cancer.
Read More
George Explores Impact of Risk Status With Cabozantinib/Nivolumab in Advanced RCC
July 19th 2024During a Case-Based Roundtable® event, Daniel George, MD, discussed the results of the CheckMate 9ER trial across favorable, intermediate, and poor risk groups in patients with advanced renal cell carcinoma.
Read More
Depth of Response With Quadruplet Regimens Considered in Newly Diagnosed Multiple Myeloma
July 18th 2024During a Case-Based Roundtable® event, Timothy Schmidt, MD, and participants discussed treatment selection for a 54-year-old patient with transplant eligible R-ISS stage 2/R2-ISS stage 3 IgG-κ myeloma.
Read More
Rossetti Reviews Myelofibrosis Risk Stratification and Outcome Data for Pacritinib
July 17th 2024During a Case-Based Roundtable® event, James M. Rossetti, DO, discussed the role of risk scoring and stratification tools and treatment for a patient with declining hemoglobin and platelet counts due to primary myelofibrosis.
Read More